The Relationship of Serum Beta Defensin-2 and Surfactant Protein A and B Levels with the Clinical Course and Prognosis of COVID-19 Infection

Year 2024, Volume: 14 Issue: 2, 162 - 169, 29.08.2024

Gülçin Şahingöz Erdal , Pınar Kasapoğlu , Tamay Seda Taşçı , Ramazan Korkusuz , Mehmet Emirhan Işık Sevgi Kalkanlı Taş , Kadriye Kart Yaşar , Nilgün Işıksaçan

Abstract

Aim: Defensin and surfactant-related peptides are antimicrobial peptides that play an essential role in the natural host defense against micro-organisms. The objective is to compare the serum beta-defensin 2 (ß-def2), serum surfactant protein-A (sSPA) and B (sSPB) levels and respiratory surfactant protein A (rSPA) and B (rSPB) levels in patients with clinically mild and severe COVID-19 pneumonia.
Material and Method: On presentation at the hospital before any treatment, venous blood samples and a nasopharyngeal smear sample were taken for rSPA and rSPB. The ß-def2, SPA, and SPB levels were advanced and analyzed using the ELISA method.
Results: The levels of acute phase reactants of ß-def2, sSPA, sSPB and white blood cell (WBC), neutrophil count, ferritin, procalcitonin, and C-reactive protein (CRP) were determined to be higher in the clinically and radiologically severe patients. The rSPA and rSPB levels showed a tendency to be lower in this patient group but not to a statistically significant level. The ß-def2, sSPA and sSPB values were determined to be positively correlated with WBC, neutrophil count, NLR, ferritin, procalcitonin, and CRP levels and negatively correlated with the albumin level.
Conclusion: ß-def2, sSPA, and sSPB, which play a role in the natural host defense, are correlated with the acute phase reactants of the clinical and radiological severity of COVID-19: WBC, neutrophil count, NLR, ferritin, procalcitonin, and CRP. In patients with severe disease, rSPA and rSPB levels tended to be low, although not statistically significant, and further studies on this subject could guide the use of surfactants in treatment.

Keywords

beta defensin-2, COVID-19, surfactant protein A, surfactant protein B

References

• 1. Boyton RJ, Openshaw PJ. Pulmonary defenses to acute respiratory infection. Br Med Bull. 2002;61:1–12.
• 2. Stolzenberg ED, Anderson GM, Ackermann MR, Whitlock RH, Zasloff M. Epithelial antibiotic-induced in disease states. Proc Natl Acad Sci. 1997;94:8686–90.
• 3. Zhao H, Zhou J, Zhang K, Chu H, Liu D, Poon VK, et al. A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep. 2016;25:22008.
• 4. Lafferty MK, Sun L, Christensen-Quick A, Lu W, GarzinoDemo A. Human beta-defensin 2 selectively inhibits HIV-1 in highly permissive CCR6+CD4+ T cells. Viruses. 2017;9:111.
• 5. Ganz T. Defensins: antimicrobial peptides of innate immunity, Nat Rev Immunol. 2003;3:710–20.
• 6. Routsias JG, Marinou D, Mavrouli M, Tsakris A, Pitiriga V. Serum β-Defensin 2, a novel biomarker for the diagnosis of acute infections. Diagnostics. 2023;13(11), 1885.
• 7. Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 2005;5:917–27.
• 8. Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology. 2006;344:119–30.
• 9. Zielecki F, Weber M, Eickmann M, Spiegelberg L, Zaki AM, Matrosovich M, et al. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J Virol. 2013;87:5300–4.
• 10. Niemeyer D, Zillinger T, Muth D, Zielecki F, Horvath G, Suliman T, et al. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J Virol. 2013;87:12489–95.
• 11. Ariki S, KojimaT, Gasa S, Saito A, Nishitani C, Takahashi M, et al. Pulmonary collectins play distinct roles in host defense against Mycobacterium avium. J Immunol. 2011;187:2586–94.
• 12. Ariki S, Nishitani C, Kuroki Y. Diverse functions of pulmonary collectins in host defense of the lung. J Biomed Biotechnol. 2012;532071.
• 13. Subramanian H, Gupta K, Lee D, Bayır AK, Ahn H, Ali H. β-Defensins activate human mast cells via Mas-related gene X2. J Immunol. 2013;191:345–52.
• 14. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol. 2005;5:58–68.
• 15. Dowton SB, Colten HR. Acute phase reactants in inflammation and infection. Semin Hematol. 1988;25:84–90.
• 16. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54.
• 17. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19–11 March 2020 https://www.who.int/dg/speeches/detail/who-directorgeneral-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 [Accessed 20 May 2020].
• 18. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes on chest CT during recovery from, novel coronavirus (COVID-19) pneumonia. Radiology. 2019;2:200370.
• 19. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019(COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–42.
• 20. Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38–42.
• 21. Han M, Xu M, Zhang Y, Liu Z, Li S, He T, et al. Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity. Med Microbiol Immunol. 2020;209:657–68.
• 22. Bashash D, Abolghasemi H, Naseri P, Cheraghali AM, Soltanpoor MJ, Imani Fooladi AA. The association of age, sex, and RT-PCR results with the lymphocyte and neutrophil counts in SARS-CoV-2 infection: a cross-sectional analysis of 1450 Iranian patients with COVID-19. Iran J Allergy Asthma Immunol. 2021;20:129–39.
• 23. Gallenga CE, Pandolfi F, Caraffa A, Kritas SK, Ronconi G, Toniato E, et al. Interleukin-1 family cytokines and mast cells: activation and inhibition. J Biol Regul Homeost Agents. 2019;33:1–6.
• 24. Klotman ME, Chang TL. Defensins in innate antiviral immunity. Nat Rev Immunol. 2006;6:447–56.
• 25. Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J Virol. 1986;60:1068–74.
• 26. Kerget B, Kerget F, Aksakal A, Aşkın S, Sağlam L, Akgün M. Evaluation of alpha defensin, IL-1 receptor antagonist, and IL18 levels in COVID-19 patients with macrophage activation syndrome and acute respiratory distress syndrome. J Med Virol. 2021;93:2090–8.
• 27. Dahmer MK, Flori H, Sapru A, Kohne J, Weeks HM, Curley MA, et al. Surfactant protein D is associated with severe pediatric acute respiratory distress syndrome, prolonged ventilation, and death in children with acute respiratory failure. Chest. 2020;158:1027–35.
• 28. Park J, Pabon M, Choi AM, Siempos II, Fredenburgh LE, Baron RM, et al. Plasma surfactant protein-D as a diagnostic biomarker for acute respiratory distress syndrome: validation in US and Korean cohorts. BMC Pulm Med. 2017;17:204.
• 29. Al-Bayatee NT, Ad’hiah AH. Human beta-defensins 2 and 4 are dysregulated in patients with coronavirus disease 19. Microbial Pathogenesis. 2021;160:105205.
• 30. Salvioni L, Testa F, Sulejmani A, Pepe F, Lovaglio PG, Berta P, et al. Surfactant protein D (SP-D) as a biomarker of SARS-CoV-2 infection. Clinica Chimica Acta. 2022;537:140–145.
• 31. Karslı E, Sabırlı R, Gören T, Kemancı A, Karı D, Türkçüer İ, et al. Evaluation of the relationship between surfactant protein D levels and COVID-19 clinical severity: a case-control study. Pamukkale Medical Journal. 2023;16(1):137–47.
• 32. Dushianthan A, Goss V, Cusack R, Grocott MPW, Postle AD. Altered molecular specificity of surfactant phosphatidycholine synthesis in patients with acute respiratory distress syndrome. Respir Res. 2014;15:128.
• 33. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:4202.
• 34. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet Lond Engl. 2020;395:497–506.
• 35. Ahlström JZ, Massaro F, Mikolka P, Feinstein R, Perchiazzi G, Basabe-Burgos O, et al. Synthetic surfactant with a recombinant surfactant protein C analogue improves lung function and attenuates inflammation in a model of acute respiratory distress syndrome in adult rabbits. Respir Res. 2019;20:245.
• 36. Bahadue FL, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2012;11:CD001456.
• 37. Veldhuizen RAW, Zuo YY, Petersen NO, Levis JF, Posmayer F. The COVID-19 pandemic: a target for surfactant therapy? Expert Review of Respiratory Medicine. 2020;15:597–608